Literature DB >> 7962041

Photodynamic therapy of experimental colonic tumours with 5-aminolevulinic-acid-induced endogenous porphyrins.

K Orth1, K König, F Genze, A Rück.   

Abstract

5-Aminolevulinic acid (5-ALA) is a precursor in the biosynthesis of haem. External application of 5-ALA leads to the formation of protoporphyrin IX, the last intermediate product before haem, which is an effective sensitiser. The 5-ALA-induced endogenous photosensitisation of tumour cells has been exploited for photodynamic therapy (PDT). Experimental human G-3 colonic tumours were transplanted into nude mice, and ten mice were treated by PDT. Ten animals served as controls. We measured a fluorescence intensity of the tumour that was about eight times higher than in the surrounding tissue; a good correlation between the fluorescence intensity and the photodynamic effect was found. Tumour growth was inhibited significantly after PDT, two tumours being destroyed completely after the second PDT treatment. In addition, on-line fluorescence detection during PDT showed a change in the intensity and the fluorescence spectrum of protoporphyrin IX caused by photobleaching and the formation of photoproducts.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962041     DOI: 10.1007/BF01245377

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  16 in total

1.  Induction of drug photosensitization in man after parenteral exposure to hematoporphyrin.

Authors:  G L Zalar; M Poh-Fitzpatrick; D L Krohn; R Jacobs; L C Harber
Journal:  Arch Dermatol       Date:  1977-10

2.  Local eradication of rat colon cancer with photodynamic therapy: correlation of distribution of photosensitiser with biological effects in normal and tumour tissue.

Authors:  H Barr; P Chatlani; C J Tralau; A J MacRobert; P B Boulos; S G Bown
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

3.  Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience.

Authors:  J C Kennedy; R H Pottier; D C Pross
Journal:  J Photochem Photobiol B       Date:  1990-06       Impact factor: 6.252

4.  The use of 5-aminolevulinic acid (ALA) in photodynamic therapy (PDT).

Authors:  P Charlesworth; T G Truscott
Journal:  J Photochem Photobiol B       Date:  1993-04       Impact factor: 6.252

5.  In vivo photoproduct formation during PDT with ALA-induced endogenous porphyrins.

Authors:  K König; H Schneckenburger; A Rück; R Steiner
Journal:  J Photochem Photobiol B       Date:  1993-05       Impact factor: 6.252

6.  Distribution and photosensitizing efficiency of porphyrins induced by application of exogenous 5-aminolevulinic acid in mice bearing mammary carcinoma.

Authors:  Q Peng; J Moan; T Warloe; J M Nesland; C Rimington
Journal:  Int J Cancer       Date:  1992-09-30       Impact factor: 7.396

7.  Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy.

Authors:  B W Henderson; S M Waldow; T S Mang; W R Potter; P B Malone; T J Dougherty
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

8.  Fluorescence distribution and photodynamic effect of ALA-induced PP IX in the DMH rat colonic tumour model.

Authors:  J Bedwell; A J MacRobert; D Phillips; S G Bown
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

9.  Photodynamic destruction of human bladder carcinoma.

Authors:  J F Kelly; M E Snell; M C Berenbaum
Journal:  Br J Cancer       Date:  1975-02       Impact factor: 7.640

10.  Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy.

Authors:  C S Loh; A J MacRobert; J Bedwell; J Regula; N Krasner; S G Bown
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

View more
  1 in total

1.  Kinetics and localisation of PpIX fluorescence after topical and systemic ALA application, observed in skin and skin tumours of UVB-treated mice.

Authors:  N van der Veen; H S de Bruijn; R J Berg; W M Star
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.